ALDX (STOCKS)
Aldeyra Therapeutics, Inc.
$1.750000
-0.010000 (-0.57%)
Prev close: $1.760000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Todd C. Brady
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $105.86M
- Employees
- 8
- P/E (TTM)
- -3.87
- P/B (TTM)
- 2.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.06 | $-0.10 | +0.0395 | +39.70% |
|
Dec 2025 (Q4)
|
$-0.10 | $-0.17 | +0.0714 | +41.66% |
|
Jun 2025 (Q2)
|
$-0.13 | $-0.25 | +0.1199 | +47.98% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.25 | +0.1199 | +47.98% |
Financial Statements
| Nonoperating Income/Loss | $1.01M |
| Research and Development | $20.65M |
| Operating Income/Loss | -$28.38M |
| Income/Loss From Continuing Operations After Tax | -$27.37M |
| Income/Loss From Continuing Operations Before Tax | -$27.37M |
| Net Income/Loss | -$27.37M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$27.37M |
| Net Income/Loss Available To Common Stockholders, Basic | -$27.37M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.45 |
| Diluted Earnings Per Share | -$0.45 |
| Basic Average Shares | 180,527,463 |
| Diluted Average Shares | 180,527,463 |
| Assets | $66.48M |
| Current Assets | $66.27M |
| Noncurrent Assets | $209.26K |
| Liabilities | $24.33M |
| Current Liabilities | $24.33M |
| Accounts Payable | $141.36K |
| Wages | $1.35M |
| Other Current Liabilities | $22.83M |
| Noncurrent Liabilities | $0.00 |
| Long-term Debt | $15.30M |
| Equity | $42.16M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $42.16M |
| Liabilities And Equity | $66.48M |
| Net Cash Flow From Operating Activities | -$25.99M |
| Net Cash Flow From Operating Activities, Continuing | -$25.99M |
| Net Cash Flow From Investing Activities | $45.48M |
| Net Cash Flow From Investing Activities, Continuing | $45.48M |
| Net Cash Flow From Financing Activities | $191.89K |
| Net Cash Flow From Financing Activities, Continuing | $191.89K |
| Net Cash Flow | $19.69M |
| Net Cash Flow, Continuing | $19.69M |
| Comprehensive Income/Loss | -$27.37M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$27.37M |
| Other Comprehensive Income/Loss | -$17.46M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.60K |